{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:49Z","timestamp":1786982749898,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100024149","name":"UCB Pharma Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00968-2","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T05:27:46Z","timestamp":1756618066000},"page":"967-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III\/IIIb Studies"],"prefix":"10.1007","volume":"26","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"L\u00f3pez Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"968_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397:487\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2.","journal-title":"Lancet"},{"key":"968_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397:475\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(21)00126-4.","journal-title":"Lancet"},{"key":"968_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385:130\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2102388.","journal-title":"N Engl J Med"},{"key":"968_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385:142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"key":"968_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40744-023-00553-1","volume":"10","author":"BW Kirkham","year":"2023","unstructured":"Kirkham BW, Egeberg A, Behrens F, et al. A comprehensive review of ixekizumab efficacy in nail psoriasis from clinical trials for moderate-to-severe psoriasis and psoriatic arthritis. Rheumatol Ther. 2023;10:1127\u201346. https:\/\/doi.org\/10.1007\/s40744-023-00553-1.","journal-title":"Rheumatol Ther."},{"key":"968_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31: e12589. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"key":"968_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/prom.S14861","volume":"2","author":"MA Radtke","year":"2011","unstructured":"Radtke MA, Langenbruch AK, Sch\u00e4fer I, et al. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1\u20136. https:\/\/doi.org\/10.2147\/prom.S14861.","journal-title":"Patient Relat Outcome Meas."},{"key":"968_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","volume":"76","author":"MC Pasch","year":"2016","unstructured":"Pasch MC. Nail Psoriasis: a review of treatment options. Drugs. 2016;76:675\u2013705. https:\/\/doi.org\/10.1007\/s40265-016-0564-5.","journal-title":"Drugs"},{"key":"968_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3899\/jrheum.201471","volume":"48","author":"GS Kaeley","year":"2021","unstructured":"Kaeley GS, Eder L, Aydin SZ, et al. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021;48:1208\u201320. https:\/\/doi.org\/10.3899\/jrheum.201471.","journal-title":"J Rheumatol"},{"key":"968_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, et al. Patient perspectives on psoriatic disease burden: results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239:621\u201334. https:\/\/doi.org\/10.1159\/000528945.","journal-title":"Dermatology"},{"key":"968_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"},{"key":"968_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82:117\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.026.","journal-title":"J Am Acad Dermatol"},{"key":"968_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","volume":"10","author":"N Wasel","year":"2020","unstructured":"Wasel N, Tha\u00e7i D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10:663\u201370. https:\/\/doi.org\/10.1007\/s13555-020-00383-x.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"968_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","volume":"81","author":"D Rigopoulos","year":"2019","unstructured":"Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81:228\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.072.","journal-title":"J Am Acad Dermatol"},{"key":"968_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/bjd.21827","volume":"187","author":"U Mrowietz","year":"2022","unstructured":"Mrowietz U, Augustin M. Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization. Br J Dermatol. 2022;187:1007\u20138. https:\/\/doi.org\/10.1111\/bjd.21827.","journal-title":"Br J Dermatol"},{"key":"968_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.clindermatol.2010.03.037","volume":"28","author":"MW Cashman","year":"2010","unstructured":"Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28:420\u20135. https:\/\/doi.org\/10.1016\/j.clindermatol.2010.03.037.","journal-title":"Clin Dermatol"},{"key":"968_CR17","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. https:\/\/doi.org\/10.3389\/fimmu.2020.01894.","journal-title":"Front Immunol"},{"key":"968_CR18","doi-asserted-by":"publisher","unstructured":"Blauvelt A, Langley RG, Lebwohl M, et al. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 [Epub ahead of print]. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.038.","DOI":"10.1016\/j.jaad.2025.04.038"},{"key":"968_CR19","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","volume":"14","author":"JF Merola","year":"2024","unstructured":"Merola JF, Gottlieb AB, Pinter A, et al. Bimekizumab efficacy in high-impact areas: pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase 3\/3b randomized controlled trials. Dermatol Ther (Heidelb). 2024;14:3291\u2013306. https:\/\/doi.org\/10.1007\/s13555-024-01295-w.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"968_CR20","doi-asserted-by":"publisher","unstructured":"Warren RB, Lebwohl M, Tha\u00e7i D, et al. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. Br J Dermatol. 2025;193:44\u201355. https:\/\/doi.org\/10.1093\/bjd\/ljaf032.","DOI":"10.1093\/bjd\/ljaf032"},{"key":"968_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188:749\u201359. https:\/\/doi.org\/10.1093\/bjd\/ljad035.","journal-title":"Br J Dermatol"},{"key":"968_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023;89:486\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063.","journal-title":"J Am Acad Dermatol"},{"key":"968_CR23","first-page":"123","volume":"34","author":"SE Cassell","year":"2007","unstructured":"Cassell SE, Bieber JD, Rich P, et al. The Modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34:123\u20139.","journal-title":"J Rheumatol"},{"key":"968_CR24","doi-asserted-by":"publisher","first-page":"1000776","DOI":"10.3389\/fpubh.2023.1000776","volume":"11","author":"P Maravilla-Herrera","year":"2023","unstructured":"Maravilla-Herrera P, Merino M, Alfonso Zamora S, et al. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Front Public Health. 2023;11:1000776. https:\/\/doi.org\/10.3389\/fpubh.2023.1000776.","journal-title":"Front Public Health"},{"key":"968_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.017.","journal-title":"J Am Acad Dermatol"},{"key":"968_CR26","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/rheumatology\/keae060","volume":"63","author":"D McGonagle","year":"2024","unstructured":"McGonagle D, Kavanaugh A, McInnes IB, et al. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford). 2024;63:3115\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/keae060.","journal-title":"Rheumatology (Oxford)"},{"key":"968_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233\u20139. https:\/\/doi.org\/10.1002\/art.24172.","journal-title":"Arthritis Rheum"},{"key":"968_CR28","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82:1162\u201370. https:\/\/doi.org\/10.1136\/ard-2023-224148.","journal-title":"Ann Rheum Dis"},{"key":"968_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81:68\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219961.","journal-title":"Ann Rheum Dis"},{"key":"968_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401:25\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02302-9.","journal-title":"Lancet"},{"key":"968_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401:38\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02303-0.","journal-title":"Lancet"},{"key":"968_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83:199\u2013213. https:\/\/doi.org\/10.1136\/ard-2023-224803.","journal-title":"Ann Rheum Dis"},{"key":"968_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105175","volume":"88","author":"J Gratac\u00f3s","year":"2021","unstructured":"Gratac\u00f3s J, Behrens F, Coates LC, et al. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: a call to action. Joint Bone Spine. 2021;88:105175. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105175.","journal-title":"Joint Bone Spine"},{"key":"968_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s13555-022-00704-2","volume":"12","author":"BE Elewski","year":"2022","unstructured":"Elewski BE, Blauvelt A, Gallo G, et al. Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis. Dermatol Ther (Heidelb). 2022;12:911\u201320. https:\/\/doi.org\/10.1007\/s13555-022-00704-2.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"968_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/ced\/llad136","volume":"48","author":"H Husein-ElAhmed","year":"2023","unstructured":"Husein-ElAhmed H, Husein-ElAhmed S. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis. Clin Exp Dermatol. 2023;48:895\u2013902. https:\/\/doi.org\/10.1093\/ced\/llad136.","journal-title":"Clin Exp Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00968-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:45:34Z","timestamp":1763048734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00968-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00968-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"30 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by UCB. This article, and its associated graphical abstract, were based on the original studies BE VIVID (NCT03370133), BE SURE (NCT03412747), BE BRIGHT (NCT03598790), and BE RADIANT (NCT03536884), sponsored by UCB. Support for third-party writing assistance for this article and its associated graphical abstract, provided by Michael Haycox, PhD, Alexa Holland, MSc, and Ria Gill, BSc, Costello Medical, UK, was funded by UCB in accordance with Good Publication Practice (GPP 2022) guidelines (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Joseph F. Merola: consultant and\/or investigator for AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB. Richard B. Warren: consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DICE Therapeutics, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma, UCB, and Union; research grants to his institution from AbbVie, Almirall, Amgen, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, and UCB; honoraria from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly and Company, Galderma, Janssen, and Novartis. Diamant Tha\u00e7i: investigator and\/or consultant\/advisor for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Galderma, Johnson & Johnson, Kyowa Kirin, LEO Pharma, L\u2019Oreal, New Bridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Takeda, Target-RWE, UCB, and Vichy; received grants from AbbVie, LEO Pharma, and Novartis. Kenneth B. Gordon: received consulting fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; research support from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, and UCB. Emi Nishida: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Taiho, Torii, and UCB. Bruce Strober: consultant (honoraria) for AbbVie, Alumis, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, CorEvitas, Dermavant, Janssen, LEO Pharma, Eli Lilly and Company, Maruho, Oruka, Meiji Seika Pharma, Protagonist, Takeda, Novartis, Pfizer, UCB, Rapt, Regeneron, Sanofi-Genzyme, and Union Therapeutics; stock options from Connect Biopharma and Mindera Health; speaker for AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, Janssen, Regeneron, and Sanofi Genzyme; scientific co-director (consulting fee): CorEvitas Psoriasis Registry; investigator for CorEvitas Psoriasis Registry; editor-in-chief (honorarium):\n                      Journal of Psoriasis and Psoriatic Arthritis\n                      . Curdin Conrad: consultant and\/or principal investigator in clinical trials for AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galderma, Incyte, Johnson & Johnson, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, Takeda, and UCB. Sarah Kavanagh: consultant for Aclipse Therapeutics, Aliada Therapeutics, Allay Therapeutics, Autobahn Therapeutics, Cognition Therapeutics, Colorado Prevention Center, Karuna Therapeutics, Kisbee Therapeutics, LB Pharmaceuticals, Nesos, Novartis, Onward Medical, PharPoint Research, Summit Analytical, Tonix Pharmaceuticals, Tornado Therapeutics, UCB, Whitsell Innovations, Worldwide Clinical Trials, and Zosano Pharma. Jos\u00e9 Manuel L\u00f3pez Pinto, Bengt Hoepken: employees and shareholders of UCB. Paolo Gisondi: consultant for AbbVie, Abiogen, Almirall, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Merck, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Sanofi, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Studies were conducted in accordance with the principles of the Declaration of Helsinki and approved by an independent review board and independent ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided informed written consent documented in accordance with local regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Underlying data from this article may be requested by qualified researchers 6\u00a0months after product approval in the USA and\/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents, which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of these data, proposals need to be approved by an independent review panel at\n                      \n                      and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password-protected portal.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Substantial contributions to study conception and design: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG; substantial contributions to analysis and interpretation of the data: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG; drafting the article or revising it critically for important intellectual content: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG; final approval of the version of the article to be published: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}